Vancomycin
描述
Vancomycin is a glycopeptide antibiotic primarily used to treat severe bacterial infections caused by Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and Clostridium difficile . It was first isolated from a soil sample in Borneo in 1956 and has since become a critical tool in combating antibiotic-resistant infections .
作用机制
万古霉素通过抑制细菌的细胞壁合成发挥作用。 它结合到细胞壁前体单元的 D-丙氨酰-D-丙氨酸末端，阻止其掺入细胞壁，从而削弱细菌细胞壁，导致细胞裂解和死亡 . 这种机制使其对革兰氏阳性菌非常有效 .
生化分析
Biochemical Properties
Vancomycin acts by binding to the D-alanyl-D-alanine moieties of the NAM/NAG-peptides, preventing the incorporation of these subunits into the peptidoglycan matrix, which forms the major structural component of Gram-positive bacterial cell walls . This interaction is non-covalent and results in the inhibition of cell wall synthesis . This compound’s activity is concentration-independent, also referred to as “time-dependent,” and its clinical activity can be affected by factors such as variable tissue distribution, inoculum size, and emerging resistance .
Cellular Effects
This compound primarily targets bacterial cells, where it disrupts cell wall synthesis, leading to cell death . It has been shown to have variable effects on different types of cells. For example, it has been found to reduce cell viability by 20% to 30% with increasing concentration up from 0.2 mg/mL . It also induces oxidative stress, as indicated by a reduction in the antioxidant activity of SOD2 and an increase in the MDA level .
Molecular Mechanism
This compound exerts its effects at the molecular level by forming an intricate network of hydrogen bonds with the D-Ala-D-Ala region of Lipid II, interfering with the peptidoglycan layer maturation process . This binding prevents the incorporation of N-acetylmuramic acid (NAM) and N-acetylglucosamine (NAG)-peptide subunits into the peptidoglycan matrix .
Temporal Effects in Laboratory Settings
The pharmacokinetic profile of this compound is complex and can be characterized by either a 2- or 3-compartment pharmacokinetic profile . In patients with normal creatinine clearance, this compound has an α-distribution phase of approximately 30 minutes to 1 hour and a β-elimination half-life of 6–12 hours . Over time, the effects of this compound can change due to factors such as the development of resistance .
Dosage Effects in Animal Models
In animal models, the effects of this compound can vary with different dosages. For instance, in beagle dogs, this compound is administered intravenously at a dose rate of 20 mg/kg over a 1-hour period at 12-hour intervals . The effects of this compound in animal models can also be influenced by factors such as the animal’s health status and the presence of other medications.
Metabolic Pathways
This compound is not appreciably metabolized and is eliminated primarily via the renal route, with more than 80% to 90% recovered unchanged in urine within 24 hours after administration of a single dose . It has been suggested that this compound disrupts amino acids metabolism, fatty acids biosynthesis, energy metabolism, and lipid metabolism .
Transport and Distribution
This compound is administered intravenously and has a volume of distribution of 0.4–1 L/kg . It penetrates into most body spaces, although the concentrations obtained are variable and somewhat dependent on the degree of inflammation present .
Subcellular Localization
This compound accumulates in lysosomes of proximal tubular cells throughout 10 days of treatment . The subcellular localization of this compound in the renal cortices of rats was determined with ultrathin sections by immunogold labeling .
准备方法
化学反应分析
万古霉素会经历各种化学反应，包括：
氧化和还原： 这些反应可以修饰万古霉素分子上的官能团，可能改变其活性。
取代反应： 常用试剂包括乙腈和甲醇，用于色谱方法.
主要产品： 主要产品是纯化的万古霉素，保留了其抗生素特性.
科学研究应用
Clinical Applications
FDA-Approved Indications:
Vancomycin is indicated for various infections, including:
- Clostridioides difficile-associated diarrhea
- Staphylococcal infections (including septicemia, skin and soft tissue infections)
- Endocarditis caused by enterococci and staphylococci
- Bone infections and lower respiratory tract infections
Off-Label Uses:
this compound is also utilized in several off-label scenarios:
- Catheter-related infections
- Bacterial meningitis
- Surgical prophylaxis
- Necrotizing skin and soft tissue infections
Research Findings
Recent studies have highlighted the efficacy of this compound in various clinical settings:
-
Topical Application in Surgical Site Infections:
A systematic review indicated that the local application of this compound powder significantly reduces the incidence of surgical site infections (SSIs) following joint arthroplasty. However, it was associated with an increased risk of complications such as delayed healing . -
Pediatric Applications:
Research has demonstrated this compound's immunomodulatory effects in pediatric patients with inflammatory bowel disease, suggesting its potential role beyond mere antibacterial action . -
Intrawound Use in Spine Surgery:
A meta-analysis involving 18 studies showed that intrawound application of this compound powder significantly lowers the odds of developing deep infections during spine surgeries compared to standard practices . The odds ratio for deep infections was found to be 0.23, indicating a substantial protective effect.
Data Table: Summary of this compound Applications
| Application Type | Description | Evidence Level |
|---|---|---|
| FDA-Approved Uses | Treats MRSA, endocarditis, bone infections | High |
| Off-Label Uses | Includes meningitis, surgical prophylaxis | Moderate |
| Topical Application | Reduces SSIs in joint surgeries | Systematic Review |
| Pediatric Immunomodulation | Affects TNF-alpha pathways in inflammatory conditions | Case Study |
| Intrawound Use in Spine Surgery | Lowers deep infection rates significantly | Meta-analysis |
相似化合物的比较
万古霉素经常与其他抗生素进行比较，例如：
利奈唑胺： 一种合成恶唑烷酮，可抑制蛋白质合成.
达托霉素： 一种脂肽，可破坏细胞膜功能.
替加环素： 一种甘氨酰环素，可抑制蛋白质合成.
替考拉宁： 另一种具有类似作用机制的糖肽类抗生素.
生物活性
Vancomycin is a glycopeptide antibiotic that plays a crucial role in the treatment of serious infections caused by Gram-positive bacteria, particularly those resistant to other antibiotics. This article delves into its biological activity, mechanisms of action, and recent research findings, including case studies and data tables.
This compound primarily exerts its antibacterial effect by inhibiting cell wall synthesis in bacteria. It binds to the D-alanyl-D-alanine terminus of cell wall precursor units, preventing their incorporation into the growing cell wall. This action leads to cell lysis and death, particularly in rapidly dividing bacteria. Additionally, this compound has been shown to alter the permeability of bacterial cell membranes and inhibit RNA synthesis, further contributing to its antimicrobial effects .
Antibacterial Spectrum
This compound is effective against a broad range of Gram-positive organisms, including:
- Staphylococcus aureus (including MRSA)
- Streptococcus pneumoniae
- Enterococcus faecium (including this compound-resistant strains)
- Clostridium difficile
Despite its effectiveness, this compound has limited activity against Gram-negative bacteria due to its large molecular size and inability to penetrate the outer membrane .
Recent Research Findings
Recent studies have focused on enhancing the efficacy of this compound through various modifications and combinations:
- Novel Derivatives : Research indicates that introducing quaternary ammonium cations into this compound can significantly improve its antibacterial activity. For instance, a derivative known as QAV-a1 showed higher survival rates in infected mice compared to standard this compound at higher doses .
- Conjugation with Cell-Penetrating Peptides (CPPs) : Studies demonstrated that conjugating this compound with CPPs like Tat (47–57) enhances its antimicrobial properties. The cytotoxicity of these conjugates was evaluated, showing varied effects on cell viability at different concentrations .
- Biofilm Activity : this compound's efficacy against biofilms is notably lower than its activity against planktonic cells. Modifications such as dipicolylamine functionalization have been explored to enhance its effectiveness against biofilm-associated infections .
Case Studies
Several case studies illustrate the clinical application of this compound:
- Case Study 1 : A patient with MRSA bacteremia was treated with this compound combined with an aminoglycoside, resulting in a successful outcome. The combination therapy demonstrated enhanced efficacy compared to monotherapy, highlighting the importance of synergistic effects in treatment .
- Case Study 2 : In a pediatric population, the emergence of resistance to this compound was monitored. Despite concerns about resistance patterns, no significant increase was observed over three decades, indicating sustained effectiveness against common pathogens .
Table 1: Efficacy of this compound Against Various Bacterial Strains
| Bacterial Strain | Minimum Inhibitory Concentration (MIC) | Resistance Status |
|---|---|---|
| Staphylococcus aureus (MRSA) | 1 µg/mL | Sensitive |
| Enterococcus faecium | 8 µg/mL | VanA phenotype |
| Streptococcus pneumoniae | 0.5 µg/mL | Sensitive |
| Clostridium difficile | 4 µg/mL | Sensitive |
Table 2: Comparative Survival Rates in In Vivo Studies
| Treatment | Dosage (mg/kg) | Survival Rate (%) |
|---|---|---|
| This compound | 40 | 33.3 |
| QAV-a1 | 40 | 100 |
属性
CAS 编号 |
1404-90-6 |
|---|---|
分子式 |
C66H75Cl2N9O24 |
分子量 |
1449.2 g/mol |
IUPAC 名称 |
48-[3-[(4S)-4-amino-5-hydroxy-4,6-dimethyloxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-22-(2-amino-2-oxoethyl)-5,15-dichloro-2,18,32,35,37-pentahydroxy-19-[[4-methyl-2-(methylamino)pentanoyl]amino]-20,23,26,42,44-pentaoxo-7,13-dioxa-21,24,27,41,43-pentazaoctacyclo[26.14.2.23,6.214,17.18,12.129,33.010,25.034,39]pentaconta-3,5,8(48),9,11,14,16,29(45),30,32,34(39),35,37,46,49-pentadecaene-40-carboxylic acid |
InChI |
InChI=1S/C66H75Cl2N9O24/c1-23(2)12-34(71-5)58(88)76-49-51(83)26-7-10-38(32(67)14-26)97-40-16-28-17-41(55(40)101-65-56(54(86)53(85)42(22-78)99-65)100-44-21-66(4,70)57(87)24(3)96-44)98-39-11-8-27(15-33(39)68)52(84)50-63(93)75-48(64(94)95)31-18-29(79)19-37(81)45(31)30-13-25(6-9-36(30)80)46(60(90)77-50)74-61(91)47(28)73-59(89)35(20-43(69)82)72-62(49)92/h6-11,13-19,23-24,34-35,42,44,46-54,56-57,65,71,78-81,83-87H,12,20-22,70H2,1-5H3,(H2,69,82)(H,72,92)(H,73,89)(H,74,91)(H,75,93)(H,76,88)(H,77,90)(H,94,95)/t24?,34?,35?,42?,44?,46?,47?,48?,49?,50?,51?,52?,53?,54?,56?,57?,65?,66-/m0/s1 |
InChI 键 |
MYPYJXKWCTUITO-BSRCFTEOSA-N |
SMILES |
CC1C(C(CC(O1)OC2C(C(C(OC2OC3=C4C=C5C=C3OC6=C(C=C(C=C6)C(C(C(=O)NC(C(=O)NC5C(=O)NC7C8=CC(=C(C=C8)O)C9=C(C=C(C=C9O)O)C(NC(=O)C(C(C1=CC(=C(O4)C=C1)Cl)O)NC7=O)C(=O)O)CC(=O)N)NC(=O)C(CC(C)C)NC)O)Cl)CO)O)O)(C)N)O |
手性 SMILES |
CC1C([C@@](CC(O1)OC2C(C(C(OC2OC3=C4C=C5C=C3OC6=C(C=C(C=C6)C(C(C(=O)NC(C(=O)NC5C(=O)NC7C8=CC(=C(C=C8)O)C9=C(C=C(C=C9O)O)C(NC(=O)C(C(C1=CC(=C(O4)C=C1)Cl)O)NC7=O)C(=O)O)CC(=O)N)NC(=O)C(CC(C)C)NC)O)Cl)CO)O)O)(C)N)O |
规范 SMILES |
CC1C(C(CC(O1)OC2C(C(C(OC2OC3=C4C=C5C=C3OC6=C(C=C(C=C6)C(C(C(=O)NC(C(=O)NC5C(=O)NC7C8=CC(=C(C=C8)O)C9=C(C=C(C=C9O)O)C(NC(=O)C(C(C1=CC(=C(O4)C=C1)Cl)O)NC7=O)C(=O)O)CC(=O)N)NC(=O)C(CC(C)C)NC)O)Cl)CO)O)O)(C)N)O |
外观 |
White to off-white solid powder |
Key on ui application |
Vancomycin is an antibiotic used to treat a number of bacterial infections. It is a member of the glycopeptide antibiotic class and is effective mostly against Gram-positive bacteria. |
沸点 |
N/A |
熔点 |
N/A |
Key on ui other cas no. |
1404-90-6 |
物理描述 |
Tan to brown solid; [HSDB] |
Pictograms |
Health Hazard |
纯度 |
>98% (or refer to the Certificate of Analysis) |
相关CAS编号 |
1404-93-9 (hydrochloride) 64685-75-2 (sulfate) |
保质期 |
When reconstituted with sterile water for injection, vancomycin hydrochloride injection is stable for 2 weeks at room temperature; the manufacturers state that reconstituted injections may be stored for 96 hours at 2 - 8 °C without substantial loss of potency. When reconstituted as directed in 0.9% sodium chloride injection or 5% dextrose injection, solutions prepared from ADD-Vantage vials of the drug are stable for 24 hours at room temperature. Vancomycin solutions containing 5 mg/mL in 0.9% sodium chloride injection or 5% dextrose injection are reportedly stable for at least 17 days when stored at 24 °C in glass or PVC containers and for at least 63 days when stored at 5 °C or -10 °C in glass containers. Following reconstitution with sterile water for injection as directed, vancomycin solutions that have been further diluted to a concentration of 5 mg/mL in 5 - 30% dextrose injection are stable when stored in plastic syringes for 24 hours at 4 eg C and then subsequently for 2 hours at room temperature. Solutions are stable for two weeks at room temp or longer if refrigerated. /Hydrochloride/ |
溶解度 |
White solid; solubility in water: greater than 100 mg/mL; moderately soluble in methanol; insoluble in higher alcohols, acetone, ether; UV max absorption (water): 282 nm (e = 40, 1%, 1 cm) /Vancomycin hydrochloride/ |
来源 |
Synthetic |
同义词 |
AB-Vancomycin Diatracin Hydrochloride, Vancomycin Sulfate, Vancomycin Vanco Azupharma VANCO-cell Vanco-saar Vancocin Vancocin HCl Vancocine Vancomicina Abbott Vancomicina Chiesi Vancomicina Combino Phar Vancomicina Norman Vancomycin Vancomycin Hexal Vancomycin Hydrochloride Vancomycin Lilly Vancomycin Phosphate (1:2) Vancomycin Phosphate (1:2), Decahydrate Vancomycin Sulfate Vancomycin-ratiopharm Vancomycine Dakota |
产品来源 |
United States |
Retrosynthesis Analysis
AI-Powered Synthesis Planning: Our tool employs the Template_relevance Pistachio, Template_relevance Bkms_metabolic, Template_relevance Pistachio_ringbreaker, Template_relevance Reaxys, Template_relevance Reaxys_biocatalysis model, leveraging a vast database of chemical reactions to predict feasible synthetic routes.
One-Step Synthesis Focus: Specifically designed for one-step synthesis, it provides concise and direct routes for your target compounds, streamlining the synthesis process.
Accurate Predictions: Utilizing the extensive PISTACHIO, BKMS_METABOLIC, PISTACHIO_RINGBREAKER, REAXYS, REAXYS_BIOCATALYSIS database, our tool offers high-accuracy predictions, reflecting the latest in chemical research and data.
Strategy Settings
| Precursor scoring | Relevance Heuristic |
|---|---|
| Min. plausibility | 0.01 |
| Model | Template_relevance |
| Template Set | Pistachio/Bkms_metabolic/Pistachio_ringbreaker/Reaxys/Reaxys_biocatalysis |
| Top-N result to add to graph | 6 |
Feasible Synthetic Routes
体外研究产品的免责声明和信息
请注意，BenchChem 上展示的所有文章和产品信息仅供信息参考。 BenchChem 上可购买的产品专为体外研究设计，这些研究在生物体外进行。体外研究，源自拉丁语 "in glass"，涉及在受控实验室环境中使用细胞或组织进行的实验。重要的是要注意，这些产品没有被归类为药物或药品，他们没有得到 FDA 的批准，用于预防、治疗或治愈任何医疗状况、疾病或疾病。我们必须强调，将这些产品以任何形式引入人类或动物的身体都是法律严格禁止的。遵守这些指南对确保研究和实验的法律和道德标准的符合性至关重要。
